Bicara Therapeutics (BCAX) Change in Accured Expenses (2023 - 2026)

Bicara Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 257.58% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.2 million (up 18.51% YoY), while the FY2025 annual figure was $2.8 million, down 57.7% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $11.7 million, up from $1.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $11.7 million in Q1 2026, with the low at -$1.8 million in Q2 2025.
• The 4-year median for Change in Accured Expenses is $991500.0 (2024), against an average of $2.5 million.
• Peak annual rise in Change in Accured Expenses reached 692.03% in 2025, while the deepest fall reached 82.57% in 2025.
• Bicara Therapeutics' Change in Accured Expenses stood at $4.2 million in 2023, then jumped by 114.21% to $9.0 million in 2024, then tumbled by 82.57% to $1.6 million in 2025, then surged by 647.29% to $11.7 million in 2026.
• Business Quant data shows BCAX's Change in Accured Expenses at $11.7 million in Q1 2026, $1.6 million in Q4 2025, and -$265000.0 in Q3 2025.